InfuSystem Holdings, Inc. provides health care services that facilitate outpatient care for durable medical equipment manufacturers and health care providers. News for INFU commonly covers financial results, segment trends and operating updates across Patient Services and Device Solutions, including oncology, pain management, wound therapy, direct payer rentals, pump and consumable sales, and biomedical services and repair.
Company updates also address revenue cycle management, payer-network and billing efficiency initiatives, relationships with DME manufacturers, contract economics, margin performance, cash flow, guidance and management presentations at investor conferences.
HPE (NYSE: HPE) outlined strategic priorities and a multi-year financial outlook at its Securities Analyst Meeting on December 10, 2025. Key items: a 10% annual dividend increase for FY26, an additional $3.0 billion share repurchase authorization (total ~$3.7 billion), and a plan to drive networking and AI infrastructure growth after the Juniper acquisition. Financial targets include non-GAAP diluted EPS ≥ $3.00 by FY2028, GAAP diluted EPS ≈ $1.93 by FY2028, and > $3.5 billion free cash flow by FY2028. FY26 guidance: revenue growth 5–10%, GAAP EPS $0.57–$0.77, non-GAAP EPS $2.20–$2.40, and FY26 free cash flow $1.5–$2.0 billion.
InfuSystem (NYSE American: INFU) announced that CEO Carrie Lachance and CFO Barry Steele will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025 at the Sheraton New York Times Square Hotel in New York City.
Management is scheduled for in-person one-on-one meetings throughout the day; investors may arrange meetings via their Craig-Hallum representative or contact Lytham Partners at 602-889-9700 or infu@lythampartners.com. The release reiterates InfuSystem’s two-platform business model: Patient Services and Device Solutions, and lists company Centers of Excellence in several U.S. states and Ontario, Canada.
InfuSystem (NYSE:INFU) reported third quarter 2025 results with net revenues of $36.5 million, up 3.3% year-over-year, and net income of $2.3 million (+25%).
Adjusted EBITDA (non-GAAP) was $8.3 million, up 6% with a margin of 22.8%. Gross profit rose 9.3% to $20.8 million and gross margin improved to 57.1%. Year-to-date net operating cash flow was $17.3 million, up 38%.
The Patient Services segment grew 7.6% to $22.4 million (wound care +115% driven by new PCD supplier), while Device Solutions declined 2.9% to $14.1 million. Company liquidity was $54.6 million. Management reaffirmed full-year 2025 guidance of net revenue growth 6–8% and Adjusted EBITDA margin ≥20%.
InfuSystem (NYSE American: INFU) will report third quarter 2025 financial results on Tuesday, November 4, 2025 before the market opens.
The company will host an investor conference call on November 4, 2025 at 9:00 a.m. Eastern Time; dial-in numbers are (833) 366-1127 or (412) 902-6773, and a live webcast will be available in the Investors section at https://ir.infusystem.com/.
A replay will be available at https://ir.infusystem.com/ for 90 days or by calling (855) 669-9658 or (412) 317-0088 with replay access code 7148856 through Tuesday, November 11, 2025. InfuSystem is a national health care service provider operating Patient Services and Device Solutions platforms and maintains Centers of Excellence in multiple U.S. states and Ontario, Canada.
InfuSystem Holdings (NYSE American: INFU), a national healthcare service provider specializing in outpatient care and durable medical equipment services, has announced its participation in the 4th Annual ROTH Healthcare Opportunities Conference. CEO Carrie Lachance and CFO Barry Steele will attend the conference on October 9, 2025, at the Metropolitan Club in New York City.
The company operates under two main platforms: Patient Services (including Oncology, Pain Management, and Wound Therapy) and Device Solutions. Management will be available for one-on-one virtual meetings throughout the conference day, which investors can arrange through their conference representative or Lytham Partners.
InfuSystem Holdings (NYSE American:INFU) reported strong Q2 2025 financial results with record net revenues of $36.0 million, up 7% year-over-year. The company achieved significant improvements across key metrics, including a 262% increase in net income to $2.6 million and a 32% rise in Adjusted EBITDA to $8.0 million.
Patient Services revenue grew 6% to $21.5 million, while Device Solutions revenue increased 8% to $14.5 million. Gross margin expanded by 5.7% to 55.2%, and Adjusted EBITDA margin improved by 4.3% to 22.3%. The company completed $3.5 million in stock repurchases during the quarter.
InfuSystem updated its 2025 guidance, lowering revenue growth expectations to 6-8% from 8-10%, but raising its Adjusted EBITDA margin forecast to 20% or higher, representing a 120 basis point increase over 2024.
InfuSystem Holdings (NYSE American: INFU), a national healthcare service provider specializing in outpatient care and durable medical equipment, has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open.
The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results. Investors can participate via phone or webcast, with a replay available until August 12, 2025.
InfuSystem operates through two platforms: Patient Services (including Oncology, Pain Management, and Wound Therapy) and Device Solutions, with operations centers across the US and Canada.
InfuSystem Holdings (NYSE American: INFU), a leading national healthcare service provider, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, before market open. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results.
InfuSystem operates under a two-platform model: Patient Services, which includes Oncology, Pain Management, and Wound Therapy businesses, providing clinic-to-home healthcare solutions; and Device Solutions, which supports the Patient Services platform through direct payer rentals, pump and consumable sales, and biomedical services. The company maintains Centers of Excellence across Michigan, Kansas, California, Massachusetts, Texas, and Ontario, Canada.
InfuSystem Holdings (NYSE American: INFU) announced a planned CEO transition, with current President and COO Carrie Lachance set to succeed Richard DiIorio as Chief Executive Officer effective May 19, 2025. DiIorio will remain available as an advisor to support the transition.
Lachance, who joined the company in 2010, has served in various leadership roles including Senior Vice President of Clinical and Customer Services and Territory Sales Manager. She has been President since 2021, COO since 2019, and a board member since 2021.
The company reaffirmed its full-year 2025 guidance, projecting revenue growth of 8-10% and an Adjusted EBITDA margin exceeding 18.8%, surpassing 2024's performance despite planned investments in business applications.